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ABSTRACT
This case study is to report and explore the etiology of a case of refractory seizures due to overdosage of phenytoin tablets. A case report from the 
Department of Neurology generated through voluntary adverse drug reaction (ADR)reporting stated phenytoin overdosage leading to refractory 
status epilepticus which did not respond to any of the antiepileptic drugs. A 33-year-old female patient with the history of consumption 15 tablets 
of phenytoin and a metal ring as part of a suicidal bid a month ago, presented with unconsciousness, persistent seizures, and gangrene of fingers. 
Magnetic resonance imaging showed generalized atrophic changes of the cerebrum and cerebellum. Electroencephalogram suggested multifocal 
onset status epilepticus. The patient did not respond to standard emergency treatment of status epilepticus with known antiepileptic drugs and was 
treated with thiopentone infusion under mechanical ventilation, which controlled her seizures as long as she was maintained under the infusion. 
Causality analysis using the World Health Organization scale categorizes this ADR as “possible”, as the patient is a known case of seizure disorder with 
additional cerebral changes. Hence, the disease could have had an influence over the toxic reaction. To conclude, seizures are a rare complication of 
phenytoin. Seizures can be prevented by evaluating therapeutic plasma concentration of phenytoin. In this case, the patient was on chronic treatment, 
and due to intentional toxicity, she progressed to a refractory state of seizures. This could have occurred because of the unique kinetic profile of 
phenytoin, small therapeutic index, genetic variation in drug metabolizing enzymes, and saturated sodium channels.
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INTRODUCTION
Phenytoin is a non-sedative antiepileptic drug that blocks the high-
frequency firing of voltage-gated sodium channels and decreases the 
release of synaptic glutamate. It is highly plasma protein bound, and 
no active metabolites are formed. Phenytoin seems to be the most 
commonly used and studied antiepileptic agent, and its side effects and 
toxicity symptoms are well documented [1]. Seizures due to phenytoin 
have been reported in few cases. The novelty of this case report is that 
we have discussed about elimination kinetics in detail.
CASE REPORT
A 33-year-old patient known case of seizure disorder on treatment for 
3 years was apparently alright till she consumed 15 tablets of phenytoin 
(100 mg)and a metal ring as she had a conflict with her mother in law. 
She went to bed normally. 8 hrs later, she developed confused irrelevant 
speech. She was able to speak and said that she consumed the tablets and 
the ring. A day later, she developed clonic jerky movements of bilateral 
upper limb and side-to-side movement of the head. The following day 
she became unconscious with persisting jerky movements. On the 
10th day, she developed dry gangrene of bilateral fingers (left 3, 4, and 
5 and right 4 and 5). The patient had continuous seizures for nearly 
2 months with bilateral pupils well reacting to light with preserved 
dolls eye movements. The right upper limb was spastic and flexed, and 
deep tendon reflexes were depressed. Magnetic resonance imaging 
(MRI) brain showed generalized atrophic changes in the cerebrum and 
cerebellum. Electroencephalogram performed during seizures revealed 
continuous run of spike-wave discharge seen in left frontal and central 
leads about 3-4 Hz in frequency (status epilepticus probably multifocal 
onset). Color Doppler was performed for the upper limb to find the 
reason for gangrene, but it was normal and there were no signs of an 
embolus. The patient was also screened for antinuclear antibodies to 
rule out any autoimmune cause of encephalitis, which was negative. 
Blood parameters and electrolytes were normal.
The patient did not respond to phenobarbital, sodium valproate, and 
diazepam. Later, she was ventilated and was on thiopentone infusion 
during which she was seizure free for a period of time.
However, on tapering the dose of thiopentone, she had intermittent 
seizures during touching, suctioning, and auditory stimulus. Later, the 
patient was put on tracheostomy and was referred to a higher center for 
further m anagement including surgery for epilepsy.
DISCUSSION
Causality analysis using the World Health Organization scale is 
categorized as “possible” because the patient is a known case of 
seizure disorders, and hence, the disease could have an influence on 
the reaction.
Acute phenytoin intoxication may be due to intentional or accidental 
consumption of phenytoin. The patient may present with varied 
symptoms ranging from nausea vomiting to seizures and death. In this 
case, it was an intentional toxicity, and the patient has progressed to a 
refractory state of seizures. Plasma concentration of phenytoin has a 
correlation with the adverse effects.
Phenytoin is a weak acid and has erratic GI absorption. Peak blood 
levels occur 3-12 hrs. Phenytoin metabolism is dose-dependent, and its 
elimination follows first-order kinetics at the low drug concentrations 
and zero-order kinetics at higher drug concentrations [2]. This change 
in kinetics reflects the saturation of metabolic pathways. Thus, very 
small increments in dosage may result in adverse effects.
The cause was not known for gangrene of her fingers. Gangrene [3]
and death [4] have been reported earlier for accidental intraarterial 
administration of phenytoin but not for oral administration present, 
MRI reveals cerebral atrophy. Although cerebral atrophy has been 
reported in chronic phenytoin ingestion [5], we cannot conclusively 
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prove that this is the reason for cerebral atrophy in this patient as we 
do not have neurological imaging taken at the initiation of the study. 
On the other hand, cerebral atrophy could be the reason for non-
responsiveness to phenytoin as inactive cells would not respond to the 
drug.
Such a problem can be prevented in other patients by choosing a 
different antiepileptic in patients who have indications of cerebral 
atrophy in neurological imaging at the time of diagnosis of epilepsy.
Pharmacokinetics
In very large oral dosage, gastrointestinal absorption can be delayed 
even to several days [6,7]. We do not have the plasma concentration 
of phenytoin for this patient. Hence, roughly calculating the plasma 
concentration with the dose ingested by the patient (1500 mg).
Pt weight - 50 kg
Volume of distribution for phenytoin is 0.7 L/kg
For this patient 0.7*50=35 L
Assuming the drug is available 90% (i.e.,) F =0.9.
Known formula for calculating the dose is as follows:
=








Plasma concentration =1500*0.9/35=37.5 mg/l or 37.5 μg/ml
T½ in therapeutic concentration is 12-36 hrs.
At higher concentrations, zero-order elimination occurs as a result of 
saturation of hydroxylation reaction, and apparent elimination half-life 
increases to 20-60 hrs [8,9].
From Fig 1,2,3,and 4 we infer that it takes 10,5,30 and 17 days 
respectively to reach therapeutic level of 10 micrograms per ml. Hence, 
from the above figures, we find that for the plasma concentration 
37.5 μg/ml to reduce to the therapeutic level of 10-20 μg/ml it will take 
5-30 days. Added to this as the patient had myoclonic seizures, she was 
started on valproate which displaces phenytoin, thereby increasing the 
free phenytoin concentration.
CONCLUSION
Seizures are a rare complication of phenytoin. Seizures can be 
prevented by evaluating therapeutic plasma concentration. In this case, 
the patient was on chronic treatment, and due to intentional toxicity, 
the patient progressed to a refractory state of seizures. This could 
have occurred because of the unique kinetic profile of phenytoin, small 
therapeutic index, and saturated the sodium channels. Another factor 
is the inter-patient variability of drug metabolism; certain individuals 
with a genetic predisposition are disposed to an increased level (slow 
metabolizers) [10].
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